Best Practices for Launching Profitable, Efficient NGS Tests for Hereditary Risk
FREE LIVE WEBINAR WITH Q&A
Held Wednesday, June 23, 2021 | 1-2 pm EDT
Next-generation sequencing (NGS) is gaining momentum, but implementing it well has its challenges
The decreasing cost of implementing NGS has many clinical laboratories considering expanding the scope and complexity of their hereditary testing services to include NGS. However, this expansion comes with a significant number of challenges, including setup, panel design, and validation, building for optimum turnaround time, and the need for specialized clinical genetic knowledge and overall scalability.
An effective strategy for selecting and implementing appropriate tertiary analysis tools and setting up a scalable interpretation workflow is critical to the success of a clinical NGS program.
The webinar, Best Practices for Launching Profitable, Efficient NGS Tests for Hereditary Risk, will discuss best practices for how molecular diagnostic labs can quickly and effectively launch NGS hereditary risk genetic testing, including:
- Market trends and considerations
- Laboratory setup and validation, data analysis, and reporting
- Selecting and implementing a tertiary analysis pipeline for variant interpretation
Reserve your seat today for this practical, in-depth webinar on Wednesday, June 23, from 1-2:00 pm EDT.
Get expert guidance and best practices on how to successfully implement and scale NGS hereditary risk testing in your lab
As NGS instrumentation and technology have evolved, the accessibility of NGS has expanded for most laboratories. As a result, NGS is becoming a routine clinical practice in oncology and pathology. However, NGS is more complex than many commonly used testing methods, and practical bioinformatic analysis is crucial to process the massive amounts of data generated on each NGS run.
During this webinar, Fabric Genomics’ Charlene Son Rigby, MBA, Chief Business Officer, and Jeanette McCarthy, MPH, PhD, Sr. Director, Scientific Programs, along with Tootie Tatum, PhD, Founder and CEO of Blackhawk Genomics, will increase attendees’ understanding of NGS workflow considerations, data interpretation and analysis, and best practices for implementation.
By attending Best Practices for Launching Profitable, Efficient NGS Tests for Hereditary Risk, attendees will:
- Learn more about the market trends and revenue opportunities for clinical laboratories to perform hereditary NGS genetic tests
- Implement effective strategies to introduce NGS into the laboratory and overcome associated challenges, aligning capabilities and resources.
- Launch reimbursed genetic panels rapidly, implement in 4 weeks, and improve turnaround time (TAT)
- Learn how AI enables the growing community of laboratories to offer NGS tests effectively
- Use the best tools to scale interpretation workflow—critical to the success of a clinical NGS program
- Confidently, quickly, and successfully implement and scale NGS hereditary risk testing!
Who should attend?
- Clinical laboratory directors
- Laboratory managers
- Clinical pathologists
- Laboratory technicians
- Those new to NGS
Your registration includes:
- The opportunity to pose specific questions and connect directly with speakers during a Q&A session
- Access to the post-webinar recording
This Webinar at a Glance
Wednesday, June 23, 2021
1 PM EDT
10 AM PDT
Your computer and/or speakerphone
Click here or call 512-264-7103
Charlene Son Rigby, MBA
Chief Business Officer
Charlene Son Rigby is responsible for customer success, business development, and regulatory at Fabric Genomics. She has spent her career building businesses at the intersection of data, technology, and life sciences. Before joining Fabric Genomics, Son Rigby was responsible for all go-to-market activities at Metamarkets, a big data analytics startup, was Vice President of Business Planning at Oracle, and Executive Director of Sales Operations at Siebel Systems, a $2B license business. Son Rigby also led product management at DoubleTwist, a bioinformatics startup. She started her career as a neuroscience researcher at Syntex (acquired by Roche). Son Rigby holds a BA in Human Biology from Stanford University and an MBA from the Haas School of Business at U.C. Berkeley.
Founder and CEO,
San Francisco, CA
Tootie Tatum is the Founder and CEO of Blackhawk Genomics. A clinical genomic scientist with over 20 years of experience in molecular diagnostics in academic medical centers and commercial laboratories, she is one of a few individuals worldwide to have developed project management and workflow systems for large genome sequencing centers. Dr. Tatum currently serves on the American Board of Bioanalysis and is a Next-Generation Sequencing (NGS) and molecular pathology specialty inspector for the College of American Pathologists (CAP). She is also the CLIA laboratory director for the UPMC Genome Center and the Discovery Life Sciences Clinical Genomics Laboratory.
Jeanette McCarthy, MPH, PhD
Sr. Director Scientific Programs
Dr. Jeanette McCarthy is a genome scientist and educator working at the forefront of precision medicine implementation. As a faculty member at Duke University, she ran research programs on genetic underpinnings of complex diseases—both infectious and chronic. In 2013 Dr. McCarthy founded Precision Medicine Advisors, an education and consulting business focused on communicating genomics to non-technical audiences, including healthcare providers, patients, and other stakeholders. She has worked with Fabric Genomics since 2013 on the development of software for genome analysis and variant interpretation and currently leads scientific programs and clinical services. Dr. McCarthy is coauthor of the book Precision Medicine: A Guide to Genomics in Clinical Practice (2016, McGraw Hill Education).